• Home
  • Ask Questions
  • Risk + Prevention
  • Diagnosis
  • Management
  • Tips + Tools
  • Site Map

THE "NEW" PROSTATE CANCER INFOLINK

Entries RSS | Comments RSS
  • Follow The "New" Prostate Cancer InfoLink news blog on TWITTER or FACEBOOK.
  • The "New" Prostate Cancer InfoLink has been developed to become a primary source of accurate, current, and topical information about prostate cancer for patients and their families.
  • A service of

    Prostate Cancer International.

    pcai_cmyk

  • Awards


    Prostate Cancer International Nonprofit Overview and Reviews on GreatNonprofits

  • Other PCI web sites

    El Cáncer de Próstata Latinoamérica

    Prostate Cancer Africa

    Prostate Cancer Caribbean

    Solidarité Prostate InfoLink

  • Copyright © 2008-18 Prostate Cancer International, Inc.

I-131-MIP-1095 to enter randomized, Phase II clinical trial

Posted on October 13, 2018 by Sitemaster

As we reported last year, a new radiopharmaceutical has entered the pack. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, injectable, Iodine-131-MIP-1095, metastatic, radiation, systenic, therapy | 3 Comments »

  • Donate

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

    • Major new survey on active surveillance and prostate cancer
    • Xofigo 2.0
    • Another new urine test for risk of prostate cancer
    • Lu-177-PSMA-617 vs Jevtana (cabazitaxel): which should I do next?
    • AS and management of Grade Group 2 prostate cancer
    • Risk for and detection of clinically significant prostate cancer in previously unbiopsied patients
    • ADT and risk for COVID-19 infection?
    • Avoiding radiation damage to salivary glands with Ac-225-PSMA-617 therapy
    • “Dose painting”: simultaneous integrated boost to the dominant intraprostatic lesion
    • SBRT for high-risk prostate cancer patients
    • Urine testing for risk of prostate cancer: a current and future perspective
    • Mediterranean diet, active surveillance, and low-risk prostate cancer: the details
    • Mediterranean diet, active surveillance, and low-risk prostate cancer
    • Whole pelvic salvage radiation may be better than precisely targeted lymph node salvage radiation
    • FDA approves first, oral LHRH antagonist
  • … and Archives

Blog at WordPress.com. WP Designer.